All > Paid Studies Orlando

Phase 2 for Non-Small Cell Lung Cancer

SCRI - TN Oncology Nashville Drug Development Unit Clinic, Nashville, TN
Non-Small Cell Lung Cancer+4 More ConditionsMRTX1133 - Drug
Eligibility
18+
All Sexes

Study Summary

This trial studies a new drug to see how safe and effective it is on patients with certain types of cancer.

Eligible Conditions
  • Advanced Solid Tumors
  • Solid Tumors
  • Non-Small Cell Lung Cancer
  • Pancreatic Adenocarcinoma
  • Colorectal Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Similar Trials

1
Participants receiving depemokimab via a SSD
1
Hepatocellular Carcinoma (HCC) Part
1
HC-7366

Study Objectives

6 Primary · 6 Secondary · Reporting Duration: 2 years

2 years
Phase 2: Duration of response (DOR)
Phase 2: Objective response rate (ORR)
Phase 2: Overall survival (OS)
Phase 2: Progression free survival (PFS)
21 Days
Phase 1: Number of Patients who Experience Dose-Limiting Toxicity
Up to 2 years
Phase 1/1b: Number of patients who experience a treatment-related adverse event
up to 4 days
Apparent total plasma clearance when dosed orally (CL/F)
Apparent volume of distribution when dosed orally (Vz/F)
Area under plasma concentration versus time curve (AUC)
Maximum observed plasma concentration (Cmax)
Terminal elimination half-life (t1/2)
Time to achieve maximal plasma concentration (Tmax)

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
Participants receiving depemokimab via a SSD
1
Hepatocellular Carcinoma (HCC) Part
1
HC-7366

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Phase 2
1 of 2
Phase 1/1B
1 of 2

Experimental Treatment

304 Total Participants · 2 Treatment Groups

Primary Treatment: Phase 2 · No Placebo Group · Phase 1 & 2

Phase 2
Drug
Experimental Group · 1 Intervention: MRTX1133 · Intervention Types: Drug
Phase 1/1B
Drug
Experimental Group · 1 Intervention: MRTX1133 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
64 Previous Clinical Trials
7,390 Total Patients Enrolled
Vicky KangStudy DirectorMirati Therapeutics Inc.

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your cancer has spread to other parts of your body and cannot be removed by surgery.
References

Frequently Asked Questions

Are there still vacancies for participants in this trial?

"This clinical trial is currently recruiting, as reported on clinicaltrials.gov. It first appeared online in March 10th 2023 and has been recently updated on July 3rd of the same year." - Anonymous Online Contributor

Unverified Answer

How many individuals are currently participating in this experimentation?

"Indeed, the details shared on clinicaltrials.gov point to this ongoing medical trial as actively searching for participants. This study was initially posted on March 10th 2023 and most recently updated on March 7th 2023; it is currently recruiting 304 patients from one location." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top